UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials

PloS one, 2011-09, Vol.6 (9), p.e22871-e22871

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

PloS one, 2012-05, Vol.7 (5), p.e36673-e36673

2012

Link zum Volltext

Verfügbarkeit prüfen

Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials

Journal of clinical epidemiology, 2018-04, Vol.96, p.63-72

2018

Link zum Volltext

Verfügbarkeit prüfen

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

PloS one, 2011-09, Vol.6 (9), p.e24798

2011

Link zum Volltext

Verfügbarkeit prüfen

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

PloS one, 2012-07, Vol.7 (7), p.e41390-e41390

2012

Link zum Volltext

Verfügbarkeit prüfen

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

PloS one, 2015-06, Vol.10 (6), p.e0127816-e0127816

2015

Link zum Volltext

Verfügbarkeit prüfen

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set

PloS one, 2013-03, Vol.8 (3), p.e59014

2013

Link zum Volltext

Verfügbarkeit prüfen

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

PloS one, 2013-10, Vol.8 (10), p.e74078-e74078

2013

Link zum Volltext

Verfügbarkeit prüfen

Clinically Relevant Genotype Interpretation of Resistance to Didanosine

Antimicrobial Agents and Chemotherapy, 2005-05, Vol.49 (5), p.1739-1744

2005

Link zum Volltext

Verfügbarkeit prüfen

Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir

Antimicrobial Agents and Chemotherapy, 2008-02, Vol.52 (2), p.491-496

2008

Link zum Volltext

Verfügbarkeit prüfen

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

PloS one, 2013-01, Vol.8 (1), p.e54381-e54381

2013

Link zum Volltext

Verfügbarkeit prüfen

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

Current HIV research, 2011-01, Vol.9 (1), p.31

2011

Link zum Volltext

Verfügbarkeit prüfen

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

Journal of acquired immune deficiency syndromes (1999), 2019-05, Vol.81 (1), p.44

2019

Link zum Volltext

Verfügbarkeit prüfen

Tenofovir and changes in renal function

AIDS (London), 2010-02, Vol.24 (4), p.619-620

Flandre, Philippe

2010

Link zum Volltext

Verfügbarkeit prüfen

Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir

Journal of acquired immune deficiency syndromes (1999), 2017-08, Vol.75 (4), p.448

2017

Link zum Volltext

Verfügbarkeit prüfen

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy

Journal of antimicrobial chemotherapy, 2014-03, Vol.69 (3), p.753-756

2014

Link zum Volltext

Verfügbarkeit prüfen

Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?

AIDS (London), 2016-06, Vol.30 (9), p.1433-1438

2016

Link zum Volltext

Verfügbarkeit prüfen

Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infection

Statistics in medicine, 2007-10, Vol.26 (24), p.4441-4454

2007

Link zum Volltext

Verfügbarkeit prüfen

Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study

Journal of acquired immune deficiency syndromes (1999), 2012-12, Vol.61 (5), p.557

2012

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1

Journal of medical virology, 2015-02, Vol.87 (2), p.187-191

2015

Link zum Volltext

Verfügbarkeit prüfen

Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy

Journal of antimicrobial chemotherapy, 2012-06, Vol.67 (6), p.1470-1474

2012

Link zum Volltext

Verfügbarkeit prüfen

Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial

Journal of antimicrobial chemotherapy, 2010-05, Vol.65 (5), p.1005-1007

2010

Link zum Volltext

Verfügbarkeit prüfen

Risk factors for raltegravir resistance development in clinical practice

Journal of antimicrobial chemotherapy, 2012-10, Vol.67 (10), p.2494-2500

2012

Link zum Volltext

Verfügbarkeit prüfen

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism

Journal of medical virology, 2012-12, Vol.84 (12), p.1853

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

ThemaHuman Immunodeficiency Virus

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

Clinically Relevant Genotype Interpretation of Resistance to Didanosine

Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

Tenofovir and changes in renal function

Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy

Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?

Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infection

Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study

Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1

Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen

Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial

Risk factors for raltegravir resistance development in clinical practice

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism

Aktive Filter

Suchergebnisse filtern